Dysfunctional Uterine Bleeding Market Research Report - Global forecast till 2023

Report / Search Code: MRFR/Pharma/3264-HCRR    Publish Date: November, 2019

Price

| Price                     | 1-user PDF : $ 4450.0 | Enterprise PDF : $ 6250.0 |

Description:

Dysfunctional Uterine Bleeding Market Information: By Type (Ovulatory), By Diagnosis (Hysteroscopy, Ultrasonography), By Treatment (Pharmacologic Treatment, Hysterectomy, Endometrial Ablation), By End User (Diagnostic Centers) - Global Forecast Till 2023

Market Synopsis of the Global Dysfunctional Uterine Bleeding Market

Dysfunctional uterine bleeding, also known as abnormal uterine bleeding, is irregular bleeding occurring in the absence of any recognizable pelvic pathology. Pregnancy is a common cause of abnormal uterine bleeding. The main causes of uterine bleeding can be fibroids in the uterus, infection of the cervix, and cancer of the uterus in some cases. Medications causing dysfunctional uterine bleeding are birth control pills, hormonal agents, and Coumadin.

Rising prevalence of uterine disorders such as uterine cancer, polycystic ovary syndrome, endometriosis, and uterine polyps drive the market growth. Furthermore, rising prevalence of uterine cancer, and demand for diagnosis and treatment measures also influence the market growth. According to the Cancer Research, in 2014, 9324 new cases of uterine cancer were diagnosed in U.K and the number is expected to increase in the near future.

According to the World Cancer Research Fund International, endometrial cancer is the sixth most common cancer in women worldwide, with 320,000 new cases diagnosed in 2012. It also stated that about 53% of endometrial cancer cases occurred in the developed countries.

The global dysfunctional uterine bleeding market is expected to grow at a CAGR of 8.2% during the forecast period.

FIGURE 1: Global Dysfunctional Uterine Bleeding Market by Region, 2016 (%)
Key Players in the Global Dysfunctional Uterine Bleeding Market

Some of the key players in this market are B. Braun Melsungen AG (Germany), Hologic Inc. (U.S.), Karl Storz GmbH & Co. KG (Germany), Medgyn Products, Inc., Olympus (Japan), Richard Wolf GmbH (Germany), Stryker (U.S.), Xion Medical GmbH (Germany), Cadila Pharmaceuticals Ltd. (India), Torrent Pharmaceuticals (India).

Segments

The global dysfunctional uterine bleeding market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of type, market is segmented into ovulatory, and anovulatory.

On the basis of diagnosis, the market is segmented into hysteroscopy, ultrasonography, dilation and curettage, endometrial biopsy, and others.

On the basis of treatment, the market is segmented into pharmacologic treatment, hysterectomy, endometrial ablation, and others. The pharmacologic treatment includes oral contraceptives, estrogen, progestins, desmopressin and others.

On the basis of end user, the market is segmented into hospitals, clinics, diagnostic centers, pharmaceutical companies, and others.

Research Methodology
Regional Analysis of the Global Dysfunctional Uterine Bleeding Market

America is the largest market for dysfunctional uterine bleeding market across the globe. The market is driven by the rising prevalence of uterine cancer and other uterine disorders among women. According to the American Cancer Institute, about 61,380 new cases of uterine cancer is estimated to be diagnosed in 2017.

Europe is the second largest market owing to an increasing demand for diagnosis and treatment measures for uterine cancer, fibroids and other disorders, and increasing emphasis on women healthcare.

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the increasing prevalence of menstrual disorders, rising awareness about causes of such disorders and early diagnosis and treatment measures among women. The market is also driven by rising prevalence of sexually transmitted diseases among women in the developing nations.

The Middle East & Africa also show a steady rise in the market owing to increasing focus on women and child health, and need of primary care services in developing regions.

Intended Audience

- Drug Manufacturers
- Drug Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

Contents:

<table>
<thead>
<tr>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of Content</td>
</tr>
<tr>
<td>1. Report Prologue</td>
</tr>
<tr>
<td>2. Market Introduction</td>
</tr>
<tr>
<td>2.1 Definition</td>
</tr>
<tr>
<td>2.2 Scope of the Study</td>
</tr>
<tr>
<td>2.2.1 Research Objective</td>
</tr>
<tr>
<td>2.2.2 Assumptions</td>
</tr>
<tr>
<td>2.2.3 Limitations</td>
</tr>
<tr>
<td>3. Research Methodology</td>
</tr>
<tr>
<td>3.1 Introduction</td>
</tr>
<tr>
<td>3.2 Primary Research</td>
</tr>
<tr>
<td>3.3 Secondary research</td>
</tr>
<tr>
<td>3.4 Market Size Estimation</td>
</tr>
<tr>
<td>4. Market Dynamics</td>
</tr>
<tr>
<td>4.1 Drivers</td>
</tr>
<tr>
<td>4.2 Restraint</td>
</tr>
<tr>
<td>4.3 Opportunities</td>
</tr>
<tr>
<td>4.4 Challenges</td>
</tr>
<tr>
<td>4.5 Macroeconomic Indicators</td>
</tr>
<tr>
<td>4.6 Technology Trends &amp; Assessment</td>
</tr>
<tr>
<td>5. Market Factor Analysis</td>
</tr>
<tr>
<td>5.1 Porters Five Forces Analysis</td>
</tr>
<tr>
<td>5.1.1 Bargaining Power of Suppliers</td>
</tr>
</tbody>
</table>
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6. Global Dysfunctional Uterine Bleeding Market, by Type
6.1 Introduction
6.2 Ovulatory
6.2.1 Market Estimates & Forecast, 2017-2023
6.3 Anovulastory
6.3.1 Market Estimates & Forecast, 2017-2023

7. Global Dysfunctional Uterine Bleeding Market, by Diagnosis
7.1 Introduction
7.2 hysteroscopy
7.2.1 Market Estimates & Forecast, 2017-2023
7.3 Ultrasonography
7.3.1 Market Estimates & Forecast, 2017-2023
7.4 Dilation and curettage
7.4.1 Market Estimates & Forecast, 2017-2023
7.5 endometrial biopsy
7.5.1 Market Estimates & Forecast, 2017-2023

8. Global Dysfunctional Uterine Bleeding Market, by Treatment
8.1 Introduction
8.2 Pharmacologic treatment
8.2.1 Market Estimates & Forecast, 2017-2023
8.3 Hysterectomy
8.3.1 Market Estimates & Forecast, 2017-2023
8.4 Endometrial ablation
8.4.1 Market Estimates & Forecast, 2017-2023

9. Global Dysfunctional Uterine Bleeding Market, by End User
9.1 Introduction
9.2 Hospital
9.2.1 Market Estimates & Forecast, 2017-2023
9.3 Clinics
9.3.1 Market Estimates & Forecast, 2017-2023
9.4 Diagnostic Centers
9.4.1 Market Estimates & Forecast, 2017-2023
9.5 Pharmaceutical Companies
9.5.1 Market Estimates & Forecast, 2017-2023

10. Global Dysfunctional Uterine Bleeding Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 UK
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa

11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments

12 Company Profiles
12.1 B. BRAUN MELSUNGEN AG
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Hologic Inc.
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 KARL STORZ GMBH & CO. KG
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Medgyn Products, Inc.
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Stryker
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Richard Wolf GmbH
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 Xion Medical GmbH
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Olympus
12.8.1 Overview
12.8.2 Product Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Others

13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Women Healthcare Industry

14 Appendix

LIST OF TABLES
Table 1 Dysfunctional Uterine Bleeding Industry Synopsis, 2017-2023
Table 2 Global Dysfunctional Uterine Bleeding Market Estimates and Forecast, 2017-2023, (USD Million)
Table 3 Global Dysfunctional Uterine Bleeding Market by Region, 2017-2023, (USD Million)
Table 4 Global Dysfunctional Uterine Bleeding Market by Types, 2017-2023, (USD Million)
Table 5 Global Dysfunctional Uterine Bleeding Market by Diagnosis, 2017-2023, (USD Million)
Table 6 Global Dysfunctional Uterine Bleeding Market by Treatment, 2017-2023, (USD Million)
Table 7 Global Dysfunctional Uterine Bleeding Market by End Users, 2017-2023, (USD Million)
Table 8 North America Dysfunctional Uterine Bleeding Market by Types, 2017-2023, (USD Million)
Table 9 North America Dysfunctional Uterine Bleeding Market by Diagnosis, 2017-2023, (USD Million)
Table 10 North America Dysfunctional Uterine Bleeding Market by Treatment, 2017-2023, (USD Million)
Table 11 North America Dysfunctional Uterine Bleeding Market by End Users, 2017-2023, (USD Million)
Table 12 US Dysfunctional Uterine Bleeding Market by Types, 2017-2023, (USD Million)
Table 13 US Dysfunctional Uterine Bleeding Market by Diagnosis, 2017-2023, (USD Million)
Figure 18 Hologic Inc.: Segmental Revenue
Figure 19 Hologic Inc.: Geographical Revenue
Figure 20 KARL STORZ GMBH & CO. KG: Key Financials
Figure 21 KARL STORZ GMBH & CO. KG: Segmental Revenue
Figure 22 KARL STORZ GMBH & CO. KG: Geographical Revenue
Figure 23 Medgyn Products, Inc.: Key Financials
Figure 24 Medgyn Products, Inc.: Segmental Revenue
Figure 25 Medgyn Products, Inc.: Geographical Revenue
Figure 26 Richard Wolf GmbH : Key Financials
Figure 27 Richard Wolf GmbH : Segmental Revenue
Figure 28 Richard Wolf GmbH : Geographical Revenue
Figure 29 Stryker: Key Financials
Figure 30 Stryker: Segmental Revenue
Figure 31 Stryker: Geographical Revenue
Figure 32 Pfizer Inc: Key Financials
Figure 33 Pfizer Inc: Segmental Revenue
Figure 34 Pfizer Inc: Geographical Revenue